Literature DB >> 8083197

The influence of apolipoprotein structure on the efflux of cellular free cholesterol to high density lipoprotein.

W S Davidson1, S Lund-Katz, W J Johnson, G M Anantharamaiah, M N Palgunachari, J P Segrest, G H Rothblat, M C Phillips.   

Abstract

The influence of apolipoprotein conformation on the ability of high density lipoprotein (HDL) to remove cellular free cholesterol (FC) has not been studied in detail. To address the effects of amphipathic alpha-helix structure on cellular FC efflux, three class A helical peptides and apolipoprotein (apo) AI were complexed to dimyristoyl phosphatidylcholine (DMPC) to make discoidal complexes that were used as acceptors of cell cholesterol. The peptides consisted of an 18-amino acid, amphipathic, alpha-helical peptide with the sequence DWLKAFYDKVAEKLKEAF (18A), a dimer of 18A covalently linked by a proline residue (37pA), and acetyl-18A-amide (Ac-18A-NH2) that has a higher alpha-helix content than the unblocked 18A molecule. The three peptides strongly mimic the lipid-binding characteristics of the amphipathic segments of apolipoproteins and form discoidal complexes with DMPC that are similar in diameter (11-12 nm) to those formed by human apoAI when reconstituted at a 2.5:1 (w:w) phospholipid to protein ratio. The abilities of these complexes to remove radiolabeled FC were compared in experiments using cultured mouse L-cell fibroblasts; efflux of FC from both the plasma membrane and the lysosomal pools was examined. For each of the acceptors, the removal of cholesterol from the plasma membrane and lysosomal pools was equally efficient. All four discoidal complexes were equally efficient cell membrane FC acceptors when compared at saturating acceptor concentrations of > 200 micrograms of DMPC/ml of medium. However, at the same lipid concentration, protein-free DMPC small unilamellar vesicles (SUV) were significantly less efficient. The initial rates of FC removal from cells at saturating concentrations of acceptor particles (Vmax) were 12, 10, 10, and 11% per h, respectively, for the complexes containing either 18A, Ac-18A-NH2, 37pA, or apoAI, but only 1% cellular FC per h for the DMPC SUV. The 10-fold higher Vmax for the apoprotein/peptide-containing acceptors was likely due to a reversible interaction of apoprotein or peptide with the plasma membrane that changed the lipid packing characteristics in such a way as to increase the rate of FC desorption from the cell surface. This interaction required amphipathic alpha-helical segments, but it was not affected by the length, number, or lipid-binding affinity of the helices. Furthermore, the efflux efficiency was not dependent on the amino acid sequence of the helical segments which suggests that this interaction is not mediated by a specific cell surface binding site.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8083197

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis.

Authors:  Torjus Skajaa; David P Cormode; Peter A Jarzyna; Amanda Delshad; Courtney Blachford; Alessandra Barazza; Edward A Fisher; Ronald E Gordon; Zahi A Fayad; Willem J M Mulder
Journal:  Biomaterials       Date:  2011-01       Impact factor: 12.479

Review 2.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  HDL as a contrast agent for medical imaging.

Authors:  David P Cormode; Juan C Frias; Yanqing Ma; Wei Chen; Torjus Skajaa; Karen Briley-Saebo; Alessandra Barazza; Kevin Jon Williams; Willem Jm Mulder; Zahi A Fayad; Edward A Fisher
Journal:  Clin Lipidol       Date:  2009-08

4.  High-density lipoprotein 3 physicochemical modifications induced by interaction with human polymorphonuclear leucocytes affect their ability to remove cholesterol from cells.

Authors:  A Cogny; V Atger; J L Paul; T Soni; N Moatti
Journal:  Biochem J       Date:  1996-02-15       Impact factor: 3.857

5.  5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.

Authors:  Marcelo J A Amar; Wilissa D'Souza; Scott Turner; Stephen Demosky; Denis Sviridov; John Stonik; Jayraz Luchoomun; Jason Voogt; Marc Hellerstein; Dmitri Sviridov; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2010-05-19       Impact factor: 4.030

Review 6.  Multiple indications for anti-inflammatory apolipoprotein mimetic peptides.

Authors:  Brian J Van Lenten; Mohamad Navab; G M Anantharamaiah; Georgette M Buga; Srinivasa T Reddy; Alan M Fogelman
Journal:  Curr Opin Investig Drugs       Date:  2008-11

7.  Effects of acyl chain length, unsaturation, and pH on thermal stability of model discoidal HDLs.

Authors:  Madhumita Guha; Donald L Gantz; Olga Gursky
Journal:  J Lipid Res       Date:  2008-05-01       Impact factor: 5.922

Review 8.  Modified natural nanoparticles as contrast agents for medical imaging.

Authors:  David P Cormode; Peter A Jarzyna; Willem J M Mulder; Zahi A Fayad
Journal:  Adv Drug Deliv Rev       Date:  2009-11-06       Impact factor: 15.470

9.  Comparison of the structural and functional effects of monomeric and dimeric human apolipoprotein A-II in high density lipoprotein particles.

Authors:  S Lund-Katz; Y M Murley; E Yon; K L Gillotte; W S Davidson
Journal:  Lipids       Date:  1996-11       Impact factor: 1.880

10.  An analysis of the role of a retroendocytosis pathway in ABCA1-mediated cholesterol efflux from macrophages.

Authors:  Loren E Faulkner; Stacey E Panagotopulos; Jacob D Johnson; Laura A Woollett; David Y Hui; Scott R Witting; J Nicholas Maiorano; W Sean Davidson
Journal:  J Lipid Res       Date:  2008-03-22       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.